BioSpace News Archive

BlueWind Medical announces its 100th patient implant in their pivotal study for treating overactive bladder symptoms using an innovative medical device the RENOVA™ iStim.

Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a new patent and data utilizing “tolerogenic dendritic cells” obtained from umbilical cord blood for suppression of Parkinson’s Disease in an animal model.

The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights to Pierre Fabre to develop and commercialize a family of human antibodies generated through the phage display human antibody Ymax®-ABL library owned by Y-Biologics.

Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of the MAGNETOM Free.Max, a new High-V magnetic resonance (MR) scanner.

Two commonly prescribed medications used by millions of Americans – one to treat Type 2 diabetes, and the other to block stomach acid production - have been found to cause potentially harmful nutritional deficiencies

CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies, today announced the appointments of Michael Fekete and Greg Tibbitts, to the Company’s board of directors.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that the Company has made significant progress on its pivotal ONWARD Phase 3 clinical trial having met 100% of its patient screening target and having achieved 90% of its patient enrollment target.

Cleveland BioLabs, Inc. today announced that the Company and Cytocom Inc.will host an investor call and live webcast on Wednesday, July 7 at 8:30 a.m. ET.

Quest Diagnostics Incorporated announced that it will report second quarter 2021 financial results on Thursday, July 22, 2021 , before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time.